TOBI: reducing the impact of pseudomonal infection

Hosp Med. 2002 Jul;63(7):421-5. doi: 10.12968/hosp.2002.63.7.1987.

Abstract

Pseudomonas aeruginosa infection is associated with impaired lung function and reduced life expectancy in cystic fibrosis patients. Tobramycin nebulizer solution (TOBI, Chiron Corporation Ltd, Hounslow) has been specifically formulated for use against P. aeruginosa infection in the lung.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Anti-Bacterial Agents / administration & dosage*
  • Cystic Fibrosis / complications*
  • Cystic Fibrosis / microbiology
  • Cystic Fibrosis / physiopathology
  • Drug Resistance
  • Forced Expiratory Volume / drug effects
  • Humans
  • Nebulizers and Vaporizers
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / physiopathology
  • Pseudomonas aeruginosa
  • Tobramycin / administration & dosage*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Tobramycin